235 related articles for article (PubMed ID: 19789304)
1. Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.
Smith KA; Meisenburg BL; Tam VL; Pagarigan RR; Wong R; Joea DK; Lantzy L; Carrillo MA; Gross TM; Malyankar UM; Chiang CS; Da Silva DM; Kündig TM; Kast WM; Qiu Z; Bot A
Clin Cancer Res; 2009 Oct; 15(19):6167-76. PubMed ID: 19789304
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination.
Tseng CW; Hung CF; Alvarez RD; Trimble C; Huh WK; Kim D; Chuang CM; Lin CT; Tsai YC; He L; Monie A; Wu TC
Clin Cancer Res; 2008 May; 14(10):3185-92. PubMed ID: 18483387
[TBL] [Abstract][Full Text] [Related]
3. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis.
Liu B; Ye D; Song X; Zhao X; Yi L; Song J; Zhang Z; Zhao Q
Vaccine; 2008 Mar; 26(10):1387-96. PubMed ID: 18272260
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
[TBL] [Abstract][Full Text] [Related]
5. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
6. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes.
Jeanbart L; Ballester M; de Titta A; Corthésy P; Romero P; Hubbell JA; Swartz MA
Cancer Immunol Res; 2014 May; 2(5):436-47. PubMed ID: 24795356
[TBL] [Abstract][Full Text] [Related]
7. Expression of a soluble IL-10 receptor enhances the therapeutic effects of a papillomavirus-associated antitumor vaccine in a murine model.
Silva JR; Sales NS; Silva MO; Aps LRMM; Moreno ACR; Rodrigues EG; Ferreira LCS; Diniz MO
Cancer Immunol Immunother; 2019 May; 68(5):753-763. PubMed ID: 30806747
[TBL] [Abstract][Full Text] [Related]
8. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710
[TBL] [Abstract][Full Text] [Related]
9. Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression.
Kanodia S; Da Silva DM; Karamanukyan T; Bogaert L; Fu YX; Kast WM
Cancer Res; 2010 May; 70(10):3955-64. PubMed ID: 20460520
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy.
Bae SH; Park YJ; Park JB; Choi YS; Kim MS; Sin JI
Clin Cancer Res; 2007 Jan; 13(1):341-9. PubMed ID: 17200373
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
[TBL] [Abstract][Full Text] [Related]
13. Fungal mannosylation enhances human papillomavirus 16 E7 therapeutic immunity against TC-1 tumors.
Wang Z; Wei C; Zhang Y; Wang W; Zhou Z; Xiao G
Oncol Rep; 2018 Jan; 39(1):425-432. PubMed ID: 29115562
[TBL] [Abstract][Full Text] [Related]
14. Photodynamic therapy-generated tumor cell lysates with CpG-oligodeoxynucleotide enhance immunotherapy efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cells.
Bae SM; Kim YW; Kwak SY; Kim YW; Ro DY; Shin JC; Park CH; Han SJ; Oh CH; Kim CK; Ahn WS
Cancer Sci; 2007 May; 98(5):747-52. PubMed ID: 17425690
[TBL] [Abstract][Full Text] [Related]
15. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
Yang Y; Che Y; Zhao Y; Wang X
Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
[TBL] [Abstract][Full Text] [Related]
16. Self-Assembled Nanofibers Elicit Potent HPV16 E7-Specific Cellular Immunity And Abolish Established TC-1 Graft Tumor.
Li S; Zhang Q; Bai H; Huang W; Shu C; Ye C; Sun W; Ma Y
Int J Nanomedicine; 2019; 14():8209-8219. PubMed ID: 31632028
[TBL] [Abstract][Full Text] [Related]
17. Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model.
Chu X; Li Y; Long Q; Xia Y; Yao Y; Sun W; Huang W; Yang X; Liu C; Ma Y
Int J Nanomedicine; 2016; 11():2417-29. PubMed ID: 27313455
[TBL] [Abstract][Full Text] [Related]
18. Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects.
Peng S; Trimble C; Alvarez RD; Huh WK; Lin Z; Monie A; Hung CF; Wu TC
Gene Ther; 2008 Aug; 15(16):1156-66. PubMed ID: 18401437
[TBL] [Abstract][Full Text] [Related]
19. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
20. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]